featured
Safety by Body Weight of Adjuvant Subcutaneous Trastuzumab for HER2+ Early Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study
Oncologist 2018 Jul 17;[EPub Ahead of Print], KH Jung, B Ataseven, M Verrill, X Pivot, M De Laurentiis, N Al-Sakaff, S Lauer, M Shing, J Gligorov, HA AzimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.